- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06807281
Długoterminowe badanie leku zwanego abrocytynibem u dzieci w wieku 2 lat i starszych z umiarkowanym do ciężkiego wyprysku
Faza 3, wieloośrodkowe, długoterminowe, otwarte badanie oceniające bezpieczeństwo i skuteczność abrocytynibu, z lub bez miejscowych leków podawanych uczestnikom pediatrycznym w wieku 2 lat i starszych z umiarkowanym do ciężaru atopowego zapalenia skóry
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Przegląd badań
Szczegółowy opis
Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Pfizer CT.gov Call Center
- Numer telefonu: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Lokalizacje studiów
-
-
-
Shanghai, Chiny, 200062
- Rekrutacyjny
- Shanghai Children's Hospital
-
Shanghai, Chiny, 200092
- Rekrutacyjny
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100045
- Rekrutacyjny
- Beijing Children's hospital, Capital Medical University
-
-
Guangdong
-
Shenzhen, Guangdong, Chiny, 518026
- Rekrutacyjny
- Shenzhen Children's Hospital
-
-
Hunan
-
Changsha, Hunan, Chiny, 410007
- Rekrutacyjny
- Hunan Children's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Chiny, 330000
- Jeszcze nie rekrutacja
- Dermatology Hospital of Jiangxi Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chiny, 310009
- Rekrutacyjny
- Hangzhou Third People's Hospital
-
-
-
-
-
Zaragoza, Hiszpania, 50009
- Rekrutacyjny
- Hospital Universitario Miguel Servet
-
-
A Coruña [LA Coruña]
-
Santiago de Compostela, A Coruña [LA Coruña], Hiszpania, 15706
- Rekrutacyjny
- CHUS - Hospital Clinico Universitario
-
-
Barcelona
-
Granollers, Barcelona, Hiszpania, 08402
- Rekrutacyjny
- Hospital General de Granollers
-
-
-
-
-
Fukuoka, Japonia, 811-1394
- Rekrutacyjny
- Fukuoka National Hospital
-
Fukuoka, Japonia, 819-0042
- Rekrutacyjny
- Saruta Dermatology Clinic
-
-
Kanagawa
-
Yokohama, Kanagawa, Japonia, 220-6208
- Rekrutacyjny
- Queen's square Medical Facilities Queen's square Dermatology and Allergology
-
-
Osaka
-
Sakai, Osaka, Japonia, 593-8324
- Rekrutacyjny
- Dermatology and Ophthalmology Kume Clinic
-
-
Tokyo
-
Setagaya-ku, Tokyo, Japonia, 157-0066
- Rekrutacyjny
- Sasamoto Children's Clinic
-
-
-
-
-
Chihuahua City, Meksyk, 31238
- Jeszcze nie rekrutacja
- Servicios Hospitalarios de Mexico S.A. DE C.V.
-
-
Mexico City
-
Mexico City, Mexico City, Meksyk, 06720
- Jeszcze nie rekrutacja
- Hospital Infantil de Mexico Federico Gomez
-
-
Nuevo León
-
Monterrey, Nuevo León, Meksyk, 64718
- Jeszcze nie rekrutacja
- Eukarya Pharmasite S.C.
-
-
Veracruz Ignacio de LA Llave
-
Veracruz, Veracruz Ignacio de LA Llave, Meksyk, 91900
- Jeszcze nie rekrutacja
- Arké SMO S.A de C.V
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polska, 20-573
- Rekrutacyjny
- LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polska, 02-625
- Rekrutacyjny
- Centrum Medyczne Evimed
-
-
Silesian Voivodeship
-
Chorzów, Silesian Voivodeship, Polska, 41-500
- Rekrutacyjny
- DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
-
Katowice, Silesian Voivodeship, Polska, 40-611
- Jeszcze nie rekrutacja
- Centrum Medyczne Angelius Provita
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polska, 90-436
- Rekrutacyjny
- Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
-
-
Świętokrzyskie Voivodeship
-
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polska, 27-400
- Rekrutacyjny
- Dermedic Jacek Zdybski
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35244
- Rekrutacyjny
- Cahaba Dermatology & Skin Health Center
-
-
Arkansas
-
North Little Rock, Arkansas, Stany Zjednoczone, 72117
- Rekrutacyjny
- Arkansas Research Trials
-
-
California
-
San Diego, California, Stany Zjednoczone, 92123
- Jeszcze nie rekrutacja
- Investigational Drug Service - Rady Childrens Hospital-San Diego
-
San Diego, California, Stany Zjednoczone, 92123
- Jeszcze nie rekrutacja
- University of California, San Diego/ Rady Children's Hospital - San Diego
-
-
Florida
-
Jacksonville, Florida, Stany Zjednoczone, 32256
- Rekrutacyjny
- Solutions Through Advanced Research
-
-
Idaho
-
Meridian, Idaho, Stany Zjednoczone, 83646
- Jeszcze nie rekrutacja
- Ada West Research - Meridian
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46250
- Rekrutacyjny
- Dawes Fretzin Clinical Research Group, LLC
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63104
- Rekrutacyjny
- Saint Louis University
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Rekrutacyjny
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
-
Greenville, South Carolina, Stany Zjednoczone, 29607
- Rekrutacyjny
- Tribe Clinical Research, LLC
-
-
Texas
-
San Antonio, Texas, Stany Zjednoczone, 78235
- Jeszcze nie rekrutacja
- Texas Dermatology and Laser Specialists
-
-
-
-
Baranya
-
Pécs, Baranya, Węgry, 7632
- Rekrutacyjny
- Pécsi Tudományegyetem Klinikai Központ
-
-
Bekes County
-
Békéscsaba, Bekes County, Węgry, 5600
- Rekrutacyjny
- Trial Pharma Kft.
-
-
Pest County
-
Budapest, Pest County, Węgry, 1033
- Rekrutacyjny
- Clinexpert Kft.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria for the Extension Cohort:
1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).
• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.
Inclusion Criteria for the De Novo Cohort:
Age
-
Children aged 6 to <12 years at the time of informed consent/assent.
• No contraception methods are required for male participants.
Disease Characteristics:
-
Participants who meet all of the following AD criteria:
- A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
- A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
- Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.
Other Inclusion Criteria:
-
Body weight ≥15 kg
Exclusion Criteria for the Extension Cohort:
Medical Conditions:
-
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
Prior/Concomitant Therapy:
-
Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.
-
Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.
Diagnostic Assessments:
-
Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.
-
Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.
Exclusion Criteria for the De Novo Cohort
Medical Conditions:
-
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
-
Have any of the following medical conditions:
-
Infections:
- Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
- History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
- Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
- Infection with HIV, hepatitis B, and/or hepatitis C
- Evidence of active TB or inadequately treated latent TB.
-
Skin Conditions:
- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
-
Other Conditions:
- Documented history of skeletal dysplasia.
- Documented history of retinal detachment.
- History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
- Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
- Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
- Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
Prior/Concomitant Therapy:
-
-
Prior treatment with a systemic JAK inhibitor for AD.
-
Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
-
Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.
Prior/Concurrent Clinical Study Experience:
-
Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.
Diagnostic Assessments:
-
Hepatic and/or renal and/or hematological abnormalities defined as:
- AST >2 x ULN
- Hemoglobin <10 g/dL
- ALT >2 x ULN
- ANC <1000/mm3
- Total bilirubin ≥1.5 x ULN
- ALC <500/mm3
- eGFR <60 mL/min/1.73 m2
- Platelets <150,000 /mm3
Other Exclusion Criteria:
-
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Extension
Patients who have completed other abrocitinib studies |
Abrocitinib administered as liquid oral suspension.
Inne nazwy:
|
|
Eksperymentalny: De novo
Patients who have not participated other abrocitinib studies |
Abrocitinib administered as liquid oral suspension.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
Ramy czasowe: 0-24 months
|
The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment. |
0-24 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants With Clinically Significant Laboratory Abnormalities
Ramy czasowe: 0-24 months
|
The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
Ramy czasowe: Baseline, 24 months
|
Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
Baseline, 24 months
|
|
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
Ramy czasowe: 0-24 months
|
Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
Ramy czasowe: 0-24 months
|
Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
Ramy czasowe: 0-24 months
|
Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points. |
0-24 months
|
|
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
Ramy czasowe: 0-24 months
|
Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
Percentage of Participants with Flares
Ramy czasowe: 0-24 months
|
Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
Ramy czasowe: 0-24 months
|
Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
Ramy czasowe: 0-24 months
|
Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
Ramy czasowe: 0-24 months
|
Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
Ramy czasowe: 0-24 months
|
Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
Ramy czasowe: 0-24 months
|
Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
Ramy czasowe: 0-24 months
|
Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
Ramy czasowe: 0-24 months
|
Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
Ramy czasowe: 0-24 months
|
Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo. |
0-24 months
|
|
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
Ramy czasowe: 0-24 months
|
Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
Ramy czasowe: 0-24 months
|
For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations. |
0-24 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Pfizer CT.gov Call Center, Pfizer
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby genetyczne, wrodzone
- Choroby układu odpornościowego
- Nadwrażliwość, natychmiastowa
- Nadwrażliwość
- Choroby skórne
- Choroby skóry, genetyczne
- Choroby skóry, egzema
- Zapalenie skóry
- Wrodzone, dziedziczne i noworodkowe choroby i nieprawidłowości
- Choroby skóry i tkanki łącznej
- Zapalenie skóry, atopowe
- Wyprysk
- Abrocitinib
Inne numery identyfikacyjne badania
- B7451031
- 2023-509124-18-00 (Identyfikator rejestru: CTIS (EU))
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .